Off-target effects of an insect cell-expressed influenza HA-pseudotyped Gag-VLP preparation in limiting postinfluenza Staphylococcus aureus infections.


Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
22 01 2020
Historique:
received: 28 06 2019
revised: 21 10 2019
accepted: 26 10 2019
pubmed: 14 11 2019
medline: 11 2 2021
entrez: 14 11 2019
Statut: ppublish

Résumé

Clinical and historical data underscore the ability of influenza viruses to ally with Staphylococcus aureus and predispose the host for secondary bacterial pneumonia, which is a leading cause of influenza-associated mortality. This is fundamental because no vaccine for S. aureus is available and the number of antibiotic-resistant strains is alarmingly rising. Hence, this leaves influenza vaccination the only strategy to prevent postinfluenza staphylococcal infections. In the present work, we assessed the off-target effects of a Tnms42 insect cell-expressed BEI-treated Gag-VLP preparation expressing the HA of A/Puerto Rico/8/1934 (H1N1) in preventing S. aureus superinfection in mice pre-infected with a homologous or heterologous H1N1 viral challenge strain. Our results demonstrate that matched anti-hemagglutinin immunity elicited by a VLP preparation may suffice to prevent morbidity and mortality caused by lethal secondary bacterial infection. This effect was observed even when employing a single low antigen dose of 50 ng HA per animal. However, induction of anti-hemagglutinin immunity alone was not helpful in inhibiting heterologous viral replication and subsequent bacterial infection. Our results indicate the potential of the VLP vaccine approach in terms of immunogenicity but suggest that anti-HA immunity should not be considered as the sole preventive method for combatting influenza and postinfluenza bacterial infections.

Identifiants

pubmed: 31718898
pii: S0264-410X(19)31472-0
doi: 10.1016/j.vaccine.2019.10.083
pii:
doi:

Substances chimiques

Hemagglutinin Glycoproteins, Influenza Virus 0
Influenza Vaccines 0
Vaccines, Virus-Like Particle 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

859-867

Subventions

Organisme : Austrian Science Fund FWF
ID : I 3490
Pays : Austria

Informations de copyright

Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Auteurs

Miriam Klausberger (M)

Department of Biotechnology, University of Natural Resources and Life Sciences (BOKU), Vienna, Austria. Electronic address: Miriam.klausberger@boku.ac.at.

Irina A Leneva (IA)

Department of Virology, I. Mechnikov Research Institute for Vaccines and Sera, Moscow, Russia.

Andrey Egorov (A)

Department of Virology, I. Mechnikov Research Institute for Vaccines and Sera, Moscow, Russia; Smorodintsev Research Institute of Influenza, Saint-Petersburg, Russia.

Florian Strobl (F)

Austrian Centre of Industrial Biotechnology (ACIB), Vienna, Austria.

Sahar M Ghorbanpour (SM)

Austrian Centre of Industrial Biotechnology (ACIB), Vienna, Austria.

Irina N Falynskova (IN)

Department of Virology, I. Mechnikov Research Institute for Vaccines and Sera, Moscow, Russia.

Alexander V Poddubikov (AV)

Department of Microbiology, I. Mechnikov Research Institute for Vaccines and Sera, Moscow, Russia.

Nailya R Makhmudova (NR)

Department of Virology, I. Mechnikov Research Institute for Vaccines and Sera, Moscow, Russia.

Artem Krokhin (A)

Department of Biotechnology, University of Natural Resources and Life Sciences (BOKU), Vienna, Austria.

Oxana A Svitich (OA)

Department of Virology, I. Mechnikov Research Institute for Vaccines and Sera, Moscow, Russia.

Reingard Grabherr (R)

Department of Biotechnology, University of Natural Resources and Life Sciences (BOKU), Vienna, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH